Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Abeona Therapeutics Inc. (ABEO), AZZ, Inc. (AZZ) & Bloom Energy Corporation (BE) 

NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. 

Abeona Therapeutics Inc. (NASDAQ: ABEO)

Class Period: May 31, 2018 – September 23, 2019
Deadline: January 2, 2020
For more info:www.bgandg.com/abeo
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Abeona’s Chemical, Manufacturing and Controls (“CMC”) and internal controls and procedures and/or compliance policies were inadequate; (2) as a result, the Company failed to provide sufficient data points on the transport stability of EB-101 to clinical sites, or else such transport stability was insufficient; (3) consequently, it was foreseeable that the U.S. Food and Drug Administration (“FDA”) would reject approval for the start of the VITAL Study until such issues were addressed; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

AZZ, Inc. (NYSE:
AZZ)

Class Period: July 3, 2018 – October 8, 2019
Deadline: January 3, 2020
For more info:www.bgandg.com/azz  
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) AZZ’s internal controls over financial reporting were not effective; (2) AZZ improperly implemented ASC 606 which resulted in improper revenue reconciliations; and (3) as a result of the foregoing, defendants’ positive statements about AZZ’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Bloom Energy Corporation (NYSE:

BE

)

Class Period: (1) purchased or otherwise acquired Bloom securities pursuant and/or traceable to Bloom’s Registration Statement issued in connection with Bloom’s July 2018 initial public stock offering (the “IPO” or “Offering”); or (2) purchased the publicly traded securities of Bloom between July 26, 2018 and September 16, 2019 (the “Class Period”)
Deadline: January 3, 2020
For more info:www.bgandg.com/be
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Bloom’s technology produced emissions comparable to that a modern natural gas plant; (2) Bloom’s estimates of useful life for its energy servers and fuel cells were inaccurate; (3) Bloom used misleading accounting to mask the effect of future servicing expenses; (4) consequently, Bloom will potentially be liable for up to $2.2 billion in undisclosed servicing liabilities; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. 

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

INVESTOR ALERT – Baxter International Inc. (BAX) – Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: January 24, 2020

PR Newswire

NEW YORK, Nov. 29, 2019 /PRNewswire/ —  Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) and certain of its officers, on behalf of shareholders who purchased Baxter securities between February 21, 2019 and October 23, 2019, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/bax.      

Bronstein, Gewirtz & Grossman, LLC

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) certain intra-Company transactions, undertaken for the purpose of generating foreign exchange gains and losses, used foreign exchange rate conventions that were not in accordance with GAAP and enabled intra-Company transactions to be undertaken after the related exchange rates were already known; (2) Baxter lacked effective internal control over financial reporting; (3) as a result, Baxter’s financial statements were misstated and would likely require correction or amendment; (4) due to Baxter’s internal investigation, it would not be able to file its quarterly report for the period ending September 30, 2019, with the SEC on a Form 10-Q in a timely manner; and (5) as a result of the foregoing, defendants’ statements about Baxter’s business and operations lacked a reasonable basis.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/bax or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Baxter you have until January 24, 2020to request that the Court appoint you as lead plaintiff.  A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/investor-alert—baxter-international-inc-bax—bronstein-gewirtz–grossman-llc-notifies-investors-of-class-action-and-lead-plaintiff-deadline-january-24-2020-300965909.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

INVESTOR ALERT – HEXO Corp. (HEXO) – Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: January 27, 2020

PR Newswire

NEW YORK, Nov. 29, 2019 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against HEXO Corp. (“HEXO”) or the “Company”) (NYSE: HEXO) and certain of its officers, on behalf of shareholders who purchased HEXO securities between January 25, 2019 and November 15, 2019, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/hexo.       

Bronstein, Gewirtz & Grossman, LLC

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) HEXO’s reported inventory was misstated as the Company was failing to write down or write off obsolete product that no longer had value; (2) HEXO was engaging in channel-stuffing in order to inflate its revenue figures and meet or exceed revenue guidance provided to investors; (3) HEXO was cultivating cannabis at its facility in Niagara, Ontario that was not appropriately licensed by Health Canada; and (4) as a result, HEXO’s public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/hexo or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in HEXO you have until January 27, 2020to request that the Court appoint you as lead plaintiff.  A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/investor-alert—hexo-corp-hexo—bronstein-gewirtz–grossman-llc-notifies-investors-of-class-action-and-lead-plaintiff-deadline-january-27-2020-300966321.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019

GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019

ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Piper Jaffrey 31st Annual Healthcare Conference in New York, New York, which takes place on December 3, 2019. Ms. King’s presentation is scheduled for 1:30 p.m. ET.

To access the live webcast and subsequent archived recordings for this presentation, please visit the GlycoMimetics website at www.glycomimetics.com.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics’ wholly-owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a Company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Investor Contact:

Shari Annes

Phone: 650-888-0902

Email: sannes@annesassociates.com

Media Contact:

Jamie Lacey-Moreira

Phone: 410-299-3310

Email: jamielacey@presscommpr.com

KEYWORDS: United States North America New York Maryland

INDUSTRY KEYWORDS: Biotechnology Health Science Pharmaceutical Research

MEDIA:

Logo
Logo

IIROC Trading Halt – CJC

Canada NewsWire

VANCOUVER, Nov. 29, 2019 /CNW/ – The following issues have been halted by IIROC:

Company: Quebec Precious Metals Corporation

TSX-Venture Symbol: CJC (all issues)

Reason: At the Request of the Company Pending News

Halt Time (ET): 9:24:13 MM AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Nutritional High Announces Financial Results for 2019 Fiscal Year End

2019 Cannabis Sales of $23.6 million, year over year growth of 306%

TORONTO, Nov. 29, 2019 (GLOBE NEWSWIRE) — Nutritional High International Inc. (“Nutritional High” or the “Company“) (CSE: EAT, OTCQB: SPLIF) is pleased to announce its financial and business results and wishes to provide highlights and commentary on the results for financial year ended July 31, 2019.

           
 
FY 2019
 
FY 2018
 
Change
Revenue $ 23,608     $ 5,815     $ 17,794  
COGS $ 18,127     $ 5,051     $ 13,076  
Gross Profit $ 5,481     $ 763     $ 4,718  
Gross Margin %   23.2 %     13.1 %     10.1 %
Lease and Interest Revenue* $ 119     $ 44     $ 75  
Operating Expenses $ 25,949     $ 9,766     $ 16,183  
Other Income (Loss) $ -6,203     $ -931     $ -5,272  
Net and Comprehensive Income/(Loss) $ -27,358     $ -9,850     $ -17,509  
Earnings/(Loss) per Share $ -0.09     $ -0.04     $ -0.052  

All Figures in Thousands CAD, unless otherwise stated
Green Therapeutics (Nevada) and Palo Verde (Colorado) financials are not consolidated in these results
*Historically, revenue was derived from lease and interest income, beginning fiscal Q3 2018, the Company started to earn revenue from Canabis sales

Fiscal 2019 Financial Highlights:

  • Revenue
       º  $23.6 million from the sale of Cannabis related products primarily via its wholly owned distributor in California, Calyx Brands Inc. (“Calyx”).
       º  Represents a year over year increase of 306%
       º  In the coming months, management fully expects to continue revenue growth from Calyx, while at the same time being able to consolidate revenue and financials from Green Therapeutics and directly enter the Colorado market.
     
  • Gross Profit of 23.2%, indicating cost of goods sold of $18.1 million including costs of product purchase, direct labor related to products sales and an allocation of overhead directly attributable to product sales. Margin improvement of 10.1% year over year.  
     
  • Operating expenses of $25.9 million, an increase of $16.2 million from prior year mainly attributed to the Company’s business and operations expansion. Key drivers are :
       º  Salaries, benefits and consulting fee: $8.4 million. The increase primarily comes from salaries and consulting fees in business acquisitions and operations in Calyx, Pasa Verde and Oregon as well as costs related to hiring and recruiting additional members to senior corporate management and several strategic advisors.
       º  General and administrative expenses: $2.8 million. This is mainly due to operations from Calyx and Pasa Verde, which were acquired in the third and fourth quarters of 2018 respectively.
       º  Sales, Marketing and Promotion: $1.1 million., primarily related to increased promotion in Calyx.
       º  Depreciation and amortization: $1.8 million, related to the acquisition of capital assets and intangible assets from Calyx and Pasa Verde in the prior year.
       º  All Other items $2.1 million, mainly composing of Q3 reserve on inventory partially offset by decrease in acquisitions and project evaluation costs. 
     
  • Other Income loss of ($6.2) million in 2019, a change of ($5.2) million versus the prior year.  In Fiscal 2019, the Company recorded the following key one-time/non-recurring items
       º  TCE $3.6 million: Q1 2019 gain on sale of interest in The Clinic Effingham in Illinois
       º  Pasa Verde LLC ($2.4) million: Mainly Q3 non-cash impairment loss of existing intangible assets and goodwill due to loss of authorization for cannabis manufacturing at Pasa Verde LLC (“Pasa Verde”) in February 2019 and a decision of the Company to apply for new local and state licenses,  offset by decrease in consideration payable in connection with the license cancellation and settlement agreement with the previous owner of Pasa Verde. 
       º  Marley License and Trademark ($5.2) million: The Company’s strategy has shifted to a focused ramp up of its manufacturing business in California, Nevada and Colorado. Additionally, management assessed that due to the changes to the market and increasing competitive pressures in Oregon and Washington, the marketability of the licensed Marley products is uncertain. As such the Company has determined to write off the associated assignment of license and trademark.   

Excluding the above, financing costs, foreign exchange gain/loss, unrealized changes in fair value of derivative liability relating to the Company’s convertible debentures and all other items, totaled another ($1.2) million.

Corporate Strategy Update

In the past year, Nutritional High has evolved and organized as two distinct lines of business – distribution and manufacturing. The Company’s distribution business, Calyx Brands, is based in California and has rapidly expanded its footprint in the past year to serve over 600 dispensaries in the State. Nutritional High’s manufacturing business started in Colorado with Palo Verde LLC and is looking to expand into Nevada, California. The Company has successfully leveraged both manufacturing and distribution for its own FLÏ™ branded product and is pursuing opportunities to do the same for other brands.

We believe it is important to have ambitious goals to match the potential of this industry, and believe we have the right people and partnerships to push in place to push the Company to the next level and beyond.

Nutritional High entered the distribution business in March 2018 with the acquisition of Calyx Brands. Since this time, Calyx has grown distribution revenues by 368% year over year and has become a leading distributor of edibles in California. The Calyx platform is unique in that it provides distribution and fulfilment supported by a strong sales and product support model.  This model has resulted in significant success with the top brands in the market and continues with four new brands being onboarded in the fourth quarter alone.

In pace with the evolution of the California market, Calyx will be introducing a hybrid model for distribution where client brands can select the level of service required for each product on an à la carte basis. Through this new service model, brand partners will have the option of selecting some or all of the following services: Core Fulfilment Services (Transportation, Warehousing, Delivery and Order Management), Optional Fulfillment Services (Title Possession and Working Capital/AR Factoring) and Enhanced Services (Field Sales and Inside Sales, Stock Out Management, Retail Merchandizing and Brand Ambassadors, Data and Analytics services). This new model positions Calyx to remain the preferred distribution partner for brands at every stage of their growth cycle.

Palo Verde, the Company’s Colorado tenant, who utilizes the Nutritional High’s knowhow and branding has established a solid and growing foothold in Colorado. Palo Verde has been expanding its sales team in Colorado and continue to improve its operations and processes. In a market that is often described as “saturated”, the FLÏ™ products have seen rapid sales growth in 2019. FLÏ™ products are produced in Colorado by Palo Verde, an independent third-party processor licensed by the State, and whose revenues have not been consolidated in the Company’s financials. Recent regulatory changes in the State have paved the way for publicly traded companies to own the means of cannabis production and NHI is looking forward to additional ease of access to the market as a result of these changes. Palo Verde remains focused on revenue growth and developing new product categories for recreational and medical markets.

In California, Nutritional High will commence manufacturing operations upon completion and licensing of its Sacramento facility. The focus will be on the development and execution of a new in-house brand in the wellness category and one that is not directly competitive to the third-party brands that are commercialized through Calyx. There will also be an opportunity to white label for the California market, enhancing facility economics and throughput. Timing of the launch of manufacturing in California will depend on availability of financing.

In Nevada, Nutritional High has been working to integrate Green Therapeutics into its current operations and will close the acquisition of a 75% interest and consolidate its revenue in the Company’s financials upon receipt of municipal and State approval. Green Therapeutics is a vertically integrated producer, extractor, manufacturer, and distributor with award winning concentrate and premium flower that is currently sold in the majority of dispensaries in the State.

During the past year, the Company saw an opportunity to be a first mover in an underexplored segment of the market – infused Asian branded products. Through the former advisor to the Prime Minister of Thailand and the newest Director of Nutritional High, the Company entered into an agreement with Golden Triangle Health Company to bring a family of established branded products to North America for infusion, sale and distribution. These will be functional, herbal products infused with CBD and other cannabinoids, and designed for either ingestion or topical use. The Company will be assessing the market viability of these products, and those that prove successful will eventually be re-commercialized in Asian countries where the legal environment permits.

Nutritional High has been fortunate to have raised both debt and equity from the Canadian capital markets and put this money to work in growing the business. The Company recognizes that the environment for financing has changed and has taken steps to focus on costs and adjust growth plans with a focus on partnerships. Through leveraging what current infrastructure in both distribution and manufacturing, Nutritional High is working to ensure that the business will be sustainable and profitable.

Business Highlights: Q4 2019 and Subsequent

  • Nutritional High strengthened its top management position with the appointment of Adam Szweras as CEO in June 2019. Mr. Szweras was a founder of the Company and has been active in its leadership since inception, most recently as Co-Chair of the board. Mr. Szweras replaced Jim Frazier, who served as CEO of the Company since July 2016, and has stepped down to pursue other business opportunities. Mr. Szweras is a securities lawyer and an investment banking professional with a successful track record of incubating and scaling cannabis focused companies. He is also currently a director of several leading cannabis companies including Aurora Cannabis Inc., Harborside Inc. and Quinsam Capital Corp.
     
  • In June 2019, the Company received its provisional distribution license from the State of California for NH Distribution California, LLC, located in Sacramento, and will commence distribution operations from this location as well, upon receipt of the Business Operating Permit (“BOP”). The Company’s distribution facilities in Oakland, Sacramento and Chatsworth together make up Nutritional High’s top tier distribution network in California, cementing its capability to service the 1,000 – 2000 dispensaries expected to open in the State. This extensive network provides the architecture towards a step change in on time delivery and pickup, delivery accuracy and minimizing storage demands for retailers. Calyx remains a leader in the distribution of cannabis products in California, and the number one distributor of edibles. It has delivered significant revenue growth from Cannabis sales, with a continuous focus on same store sales growth and expanding its service footprint to currently 600+ retail stores in the State of California. Simultaneously, it has built a robust data warehouse from its millions of sales transactions that can enable top tier market intelligence and analytics relating to both product categories/segments and geographic demand.
     
  • Since May 2019, Calyx onboarded 9 new brand partners and the Company expects further substantial onboarding over the next 6 months. Through its revamped model featuring flexible à la carte service offerings, Calyx is proving to be the premier distribution option for brands at every stage of their growth cycle.
     
  • In May 2019, the Company and Green Therapeutics amended the MIPA (“Amended Agreement”) to exclude certain assets and accompanying intellectual property which were not core to Nutritional High’s manufacturing and distribution focused business model, reducing the purchase price by 50% to USD $9 million. Under the Amended Agreement, Green Therapeutics will retain its currently operating cultivation and manufacturing licenses, a dispensary license, and a distribution license. By reducing the purchase price and only acquiring the most accretive assets, the amended agreement allows the Company to remain lean and focused on its core value proposition and drive shareholder value. Closing is pending approval by Nevada State and municipal authorities. Green Therapeutics’ financials are not yet included in Nutritional High’s financial reporting.
     
  • In Colorado, the Company currently leases its Pueblo property and equipment to Palo Verde LLC (“Palo Verde”), an independent third-party processor licensed by the State of Colorado that produces the Company’s branded. In May 2019, Colorado Governor Jared Polis signed into law HB19-1090 – “Publicly Licensed Marijuana Companies” which repeals the provision that prohibits publicly traded companies from holding a marijuana license. The Bill was passed by the Colorado Legislature on April 27, 2019, and was sponsored by two Democrats and two Republicans. The new law paves the way for Nutritional High to potentially gain direct ownership interest in MED-licensed entities. Palo Verde has already achieved significant revenue growth in 2019 and is equally focused on the development of new product categories for the recreational and medical markets. Palo Verde’s financial results are currently not consolidated in the Company’s financials.
     
  • In October 2019, the Company positioned itself to be a first mover in an underexplored segment of the market by entering a binding framework agreement with Golden Triangle Health Company Ltd. (“Golden Triangle”) to manufacture and distribute Asian branded products in North America. Golden Triangle is a Thailand-based health and wellness company with a strong family of brands (the “Brands”) looking to break into the North American market. Nutritional High will be responsible for providing North American market assessments for the Brands’ products, and for those products selected will be responsible for infusion, packaging, marketing, distribution and sales in jurisdictions where those products are legal.
     
  • The Company amended its asset purchase agreement which was previously closed in escrow pending regulatory approval, to recast it as a share purchase agreement to better streamline operations and simplify regulatory compliance. The Company now holds an aggregate of 805 interest in Calyx for no additional consideration, with the option to purchase the remaining 20% for nominal consideration.
  • In November 2019, the Company reached a settlement agreement with TKO Products LLC (“TKO”) whereby the Company accepted a settlement for a total receipt of US$325,000. The settlement agreement releases all matters including TKO’s counterclaim (see The Company’s press release dated July 25, 2019).

About Nutritional High International Inc.

Nutritional High is focused on developing, manufacturing and distributing products under recognized brands in the cannabis products industry, with a specific focus on edibles and oil extracts for medical and adult recreational use. The Company works exclusively with licensed facilities in jurisdictions where such activity is permitted and regulated by state law.

The Company follows a vertically integrated model with a fully developed strategy for acquisitions in extraction, production, sales, and distribution sectors of the cannabis industry. Nutritional High has brought its flagship FLÏ™ edibles and extracts product line from production to market through its wholly owned subsidiaries in California and Oregon, as well as Colorado where its FLÏ™ products are manufactured by a third-party licensed producer. In California, the Company distributes its products and products manufactured by other leading producers through its wholly owned distributor Calyx Brands Inc. and is entering the Nevada, Washington State and Canadian markets in the near future.

For updates on the Company’s activities and highlights of the Company’s press releases and other media coverage, please follow Nutritional High on Facebook, Twitter and Instagram or visit www.nutritionalhigh.com.

For further information, please contact:

David Posner

Chair of the Board

Nutritional High International Inc.
647-985-6727
Email: dposner@nutritionalhigh.com

Ethan Karayannopoulos

Director, Investor Relations

Nutritional High International Inc.
416-777-6175
Email: ethan@nutritionalhigh.com  

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR OTC MARKETS GROUP INC., NOR THEIR REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Risks that may have an impact on the ability for these events to be achieved include completion of due diligence, negotiation of definitive agreements and receipt of applicable approvals. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act“), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulation S under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. Some of the risks and other factors that could cause actual results to differ materially from those expressed in forward-looking information expressed in this press release include, but are not limited to: obtaining and maintaining regulatory approvals including acquiring and renewing U.S. state, local or other licenses, the uncertainty of existing protection from U.S. federal or other prosecution, regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, market and general economic conditions of the cannabis sector or otherwise.

 

Artprice by ArtMarket.com: Hong Kong – Capital of the New Hi-Lite Movement – Remains Unperturbed!

PR Newswire

PARIS, Nov. 29, 2019 /PRNewswire/ — Despite demonstrations, violent clashes and turbulent elections, Hong Kong’s art market has held up well and even posted excellent auction results. Last Saturday, 23 November, Christie’s finished its session of 20th Century & Contemporary Art Evening Sale with a total of more than $136 million. In 2018, the same session totaled just $52 million.

Liu Ye (1964) - Little mermaid, 2004 - left, Takashi Murakami (1962) - Dazzling Circus, 2013 - center, Mr. (1969) – Don’t go anywhere, 2006 - right

For the time being, the Art Basel fair is therefore still on for March 2020. With these latest results, Hong Kong has shown that it is still the world’s leading marketplace for many of the finest Asian signatures of 20th century art. However, it also proved capital for new movement that has become essential to understanding the evolution of today’s Art Market: Hi-Lite.

thierry Ehrmann, Artprice founder and CEO of ArtMarket.com: “Hong Kong is a bit like Silicon Valley: a small corner of the world on which all eyes are fixed! At one and the same time, elections have shaken the city, Alibaba has accomplished the world’s biggest IPO of the year, and a series of new records have been hammered in its auction rooms. The Hong Kong art market is promoting what will perhaps be the first major art movement of the 21st century: an art advocating greater frivolity in an uninhibitedly kitsch manner, which Christie’s has baptised Hi-Lite.”


Hi-Lite: the first major artistic movement of the 21st century?

Christie’s ended its major evening sale with a separate section dubbed Hi-Lite, and a specific catalogue bringing together artists, “whose neo-pop aesthetic and connection to commercial art, cartoons and street culture have gained them a global cult following. Many of the pieces selected for this sale employ a similar visual style featuring bold flattened forms, bright colors and clean lines, referencing images appropriated from popular media and fashion, music, graffiti and animation.

With only 16 lots, this small sale nevertheless crystallised one of the main trends driving today’s Art Market. The Hi-Lite movement, like the sale, is based primarily on three core signatures… three of the most successful artists on the secondary market: Kaws, Yoshitomo Nara and Takashi Murakami.

The Christie’s catalogue goes on to explain the title chosen by the auction house: “Hi-Lite: these artists produce work that is ‘lite’ – a word that is sometimes used to describe things that are easy to understand and enjoy, the opposite of heavy. Yet each of these artists also elevates his medium and subject, bringing elements of pop, fashion, manga and street culture to a higher level.”

The Hi-Lite session was very successful with all 16 lots fetching within or above their estimates.


Hong Kong in a positive spiral

In reality, the Hi-Lite movement goes far beyond the Christie’s session bearing that name. The extraordinary performances of Liu Ye (1964) and Ayoko Rokkaku (1982), for example, over the past nine months, are clearly part of this new dynamic… a dynamic with global momentum, but in which Hong Kong is playing a leading role.

As is now customary, Hong Kong’s leading auction houses agreed not to hold their major sessions simultaneously in the first and the second semester of the year. In the recent round of sales, Christie’s and Phillips waited until the end of November, whereas Sotheby’s, Poly Auction, China Guardian and Bonhams held their sales at the beginning of October. 

This agreement has clearly benefited the Hong Kong market. The past two months have seen a large number of auction records hammered for artists from all periods of creation, from Old Masters to emerging artists.

Top 10 New Artist Records in Hong Kong during H2 2019

  • San Yu – Five Nudes (1950) – $39 million (Christie’s)
  • Yoshitomo Nara – Knife behind back (2000) – $25 million (Sotheby’s)
  • Whan-Ki Kim – 05-IV-71 #200 (Universe) (1971) – $13 million (Christie’s)
  • Liu YeSmoke (2001/02) – $6.7 million (Sotheby’s)
  • Huang Daozhonu – Collection of poems (17th c.) – $5.5 million (Christie’s)
  • Zheng WuchangLandscapes (1939) – $2.1 million (Sotheby’s)
  • Eddie MartinezHigh flying bird (2014) – $2 million (Christie’s)
  • Li ChenDragon riding Buddha (2001) – $1.4 million (China Guardian)
  • Fei Danxu – Tour of Tao Guang temple (1834) – $1.3 million (Christie’s)

Copyright 1987-2019 thierry Ehrmann www.artprice.com – www.artmarket.com

About Artmarket:

Artmarket.com is listed on Eurolist by Euronext Paris, SRD long only and Euroclear: 7478 – Bloomberg: PRC – Reuters: ARTF.

Discover Artmarket and its Artprice department on video: https://en.artprice.com/video

Artmarket and its Artprice department was founded in 1997 by its CEO, thierry Ehrmann. Artmarket and its Artprice department is controlled by Groupe Serveur, created in 1987.

See certified biography in Who’s who ©:

https://imgpublic.artprice.com/img/wp/sites/11/2019/10/biographie_oct2019_WhosWho_thierryEhrmann.pdf

Artmarket is a global player in the Art Market with, among other structures, its Artprice department, world leader in the accumulation, management and exploitation of historical and current art market information in databanks containing over 30 million indices and auction results, covering more than 700,000 artists.

Artprice Images® allows unlimited access to the largest Art Market image bank in the world: no less than 180 million digital images of photographs or engraved reproductions of artworks from 1700 to the present day, commented by our art historians.

Artmarket with its Artprice department accumulates data on a permanent basis from 6300 Auction Houses and produces key Art Market information for the main press and media agencies (7,200 publications). Its 4.5 million ‘members log in’ users have access to ads posted by other members, a network that today represents the leading Global Standardized Marketplace® to buy and sell artworks at a fixed or bid price (auctions regulated by paragraphs 2 and 3 of Article L 321.3 of France’s Commercial Code).

Artmarket with its Artprice department, has been awarded the State label “Innovative Company” by the Public Investment Bank (BPI) (for the second time in November 2018 for a new period of 3 years) which is supporting the company in its project to consolidate its position as a global player in the market art.

Artprice by Artmarket’s 2018 Global Art Market Report published in March 2019: https://fr.artprice.com/artprice-reports/le-marche-de-lart-en-2018

Index of press releases posted by Artmarket with its Artprice department:

http://serveur.serveur.com/press_release/pressreleasefr.htm

Follow all the Art Market news in real time with Artmarket and its Artprice department on Facebook and Twitter:

https: // www .facebook.com / artpricedotcom  (4.5 million followers)

https://twitter.com/artmarketdotcom

https://twitter.com/artpricedotcom

Discover the alchemy and universe of Artmarket and its artprice department http: //web.artprice.com/video headquartered at the famous Organe Contemporary Art Museum “The Abode of Chaos” (dixit The New York Times): https://issuu.com/demeureduchaos/docs/demeureduchaos-abodeofchaos-opus-ix-1999-2013

L’Obs – The Museum of the Future: https://youtu.be/29LXBPJrs-o

https://www.facebook.com/la.demeure.du.chaos.theabodeofchaos999 
(4 million followers)

https://vimeo.com/124643720

https://www.facebook.com/the.demeure.du.chaos.theabodeofchaos999

Photo – https://mma.prnewswire.com/media/1037451/Artprice.jpg
Logo – https://mma.prnewswire.com/media/1009603/Art_Market_logo.jpg

Contact Artmarket.com and its Artprice department
Contact: thierry Ehrmann, ir@artmarket.com

 

Art Market logo (PRNewsfoto/Artprice.com)

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/artprice-by-artmarketcom-hong-kong–capital-of-the-new-hi-lite-movement–remains-unperturbed-300966852.html

SOURCE Artprice.com

Criticality’s Korent™ Line of CBD Products Launches Holiday Gift Packs

Criticality’s Korent™ Line of CBD Products Launches Holiday Gift Packs

Korent’s expertly-crafted and responsibly-produced CBD oil drops, roll-ons and balms are available in three holiday bundles in time for Cyber Monday.

WILSON, N.C.–(BUSINESS WIRE)–
Criticality, LLC, a North Carolina-based industrial hemp company, today announced that starting on Cyber Monday it will offer three holiday gift packs featuring full-sized selections of its cannabidiol (CBD) products under the Korent™ brand. The gift packs will be for sale on Korent’s website, www.korenthemp.com, as well as at select retailers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191129005238/en/

Korent's expertly-crafted and responsibly-produced CBD oil drops, roll-ons and balms are available in three holiday bundles in time for Cyber Monday. (Photo: Business Wire)

Korent’s expertly-crafted and responsibly-produced CBD oil drops, roll-ons and balms are available in three holiday bundles in time for Cyber Monday. (Photo: Business Wire)

The gift pack options enable consumers to experience a range of Korent’s expertly-crafted, responsibly-produced, fully-traceable CBD products at up to $20 off MSRP. The options include Korent’s CBD oil drops and roll-on liniments, as well as its brand new CBD balm designed to soothe and address discomfort without a sticky texture or medicinal smell. All gift packs come in bright green boxes for easy gifting.

“CBD products make a great gift, whether for a loved one or for yourself, particularly when it comes to making it through the holiday season,” said Brian Moyer, Chief Executive Officer of Criticality. “Our products provide traceability and independent testing to the consumer allowing us to provide consumers with traceable, consistent and high-quality products. We’re excited to offer customers a range of products, including our new CBD balm, in these packs so they can experience the different ways CBD can be incorporated into their wellness routine.”

Pack No. 1 features Korent’s 450mg Vanilla Mint CBD Oil Drops for $39.99. Pack No. 2 includes the same oil drops, as well as Korent’s 200mg Cooling CBD roll-on liniment for $69.99. Pack No. 3 offers the oil drops and the roll-on liniment as well as Korent’s 100mg CBD Balm for $89.99. Consumers will receive free shipping on any purchase that includes a holiday pack through Dec. 21, as well as discounts on additional Korent purchases.

All CBD products produced by Criticality are crafted from carefully cultivated hemp grown by U.S. farmers. Prior to processing, the hemp is analyzed and validated for cannabinoid levels and potential contaminants by independent, third-party laboratories. Criticality uses natural, environmentally-friendly methods to extract CBD oil from plant material without the use of harsh chemicals. After verified material is processed, it is formulated into our Korent products and subjected to further analysis and validation for quality and transparency.

For more information about Korent products, visit www.korenthemp.com.

About Criticality

Criticality is a vertically-integrated North Carolina-based industrial hemp company that takes a science-based approach to the extraction, refinement and formulation of high-quality, transparent industrial hemp derived products. Criticality partners with Pyxus International, Inc. (NYSE: PYX), a provider of responsibly produced, independently verified, sustainable and traceable agricultural products, ingredients and services, to source, process and produce industrial hemp and hemp products under North Carolina’s Industrial Hemp Pilot Program.

Ellen Saksen

Criticality, LLC

(412) 491-7065

esaksen@criticalitync.com

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Alternative Medicine Retail Health Other Retail Agriculture Natural Resources Specialty

MEDIA:

Photo
Photo
Korent’s expertly-crafted and responsibly-produced CBD oil drops, roll-ons and balms are available in three holiday bundles in time for Cyber Monday. (Photo: Business Wire)

IIROC Trading Halt – BARI

Canada NewsWire

VANCOUVER, Nov. 29, 2019 /CNW/ – The following issues have been halted by IIROC:

Company: Barrian Mining Corp.

TSX-Venture Symbol: BARI (all issues)

Reason: At the Request of the Company Pending News

Halt Time (ET): 8:58 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Eaton Vance Closed-End Funds Release Estimated Sources Of Distributions

PR Newswire

BOSTON, Nov. 29, 2019 /PRNewswire/ — The Eaton Vance closed-end funds listed below released today the estimated sources of their November distributions (each a “Fund”).  This press release is issued as required by the Funds’ managed distribution plan (Plan) and an exemptive order received from the U.S. Securities and Exchange Commission.  The Board of Trustees has approved the implementation of the Plan to make monthly, as noted below, cash distributions to common shareholders, stated in terms of a fixed amount per common share. This information is sent to you for informational purposes only and is an estimate of the sources of the November distribution.  It is not determinative of the tax character of a Fund’s distributions for the 2019 calendar year. Shareholders should note that each Fund’s total regular distribution amount is subject to change as a result of market conditions or other factors.


IMPORTANT DISCLOSURE
:  You should not draw any conclusions about each Fund’s investment performance from the amount of this distribution or from the terms of each Fund’s Plan.  Each Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur for example, when some or all of the money that you invested in each Fund is paid back to you. A return of capital distribution does not necessarily reflect each Fund’s investment performance and should not be confused with “yield” or “income.”  The amounts and sources of distributions reported in this notice are only estimates and are not being provided for tax reporting purposes.  The actual amounts and sources of the amounts for accounting and/or tax reporting purposes will depend upon each Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. Each Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

The following tables set forth estimates of the sources of each Fund’s November distribution and its cumulative distributions paid for its fiscal year through November 29, 2019, and information relating to each Fund’s performance based on its net asset value (NAV) for certain periods.



Eaton Vance Enhanced Equity Income Fund (NYSE: EOI)

Distribution Period: 

November- 2019

Distribution Amount per Common Share: 

$0.0898

Distribution Frequency:

Monthly

Fiscal Year End:

September

Source

Current Distribution

% of Current

Distribution

Cumulative

Distributions

for the Fiscal

Year-to-Date

% of the Cumulative

Distributions for the Fiscal

Year-to-Date

Net Investment Income

$0.0105

11.70%

$0.0201

11.20%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Return of Capital or Other Capital Source(s)

$0.0793

88.30%

$0.1595

88.80%

Total per common share

$0.0898

100.00%

$0.1796

100.00%

Average annual total return at NAV for the 5-year period ended on October 31, 2019 1

8.49%

Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2019 2

7.09%

Cumulative total return at NAV for the fiscal year through October 31, 2019 3

1.53%

Cumulative fiscal year to date distribution rate as a percentage of NAV as of October 31, 2019 4

0.59%



Eaton Vance Enhanced Equity Income Fund II (NYSE: EOS)

Distribution Period: 

November- 2019

Distribution Amount per Common Share: 

$0.0988

Distribution Frequency:

Monthly

Fiscal Year End:

December

Source

Current Distribution

% of Current

Distribution

Cumulative

Distributions

for the Fiscal

Year-to-Date

% of the Cumulative

Distributions for the Fiscal

Year-to-Date

Net Investment Income

$0.0000

0.00%

$0.0000

0.00%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.0988

100.00%

$1.0868

100.00%

Return of Capital or Other Capital Source(s)

$0.0000

0.00%

$0.0000

0.00%

Total per common share

$0.0988

100.00%

$1.0868

100.00%

Average annual total return at NAV for the 5-year period ended on October 31, 2019 1

10.49%

Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2019 2

7.09%

Cumulative total return at NAV for the fiscal year through October 31, 2019 3

19.78%

Cumulative fiscal year to date distribution rate as a percentage of NAV as of October 31, 2019 4

5.91%



Eaton Vance Risk-Managed Diversified Equity Income Fund (NYSE: ETJ)

Distribution Period: 

November- 2019

Distribution Amount per Common Share: 

$0.0760

Distribution Frequency:

Monthly

Fiscal Year End:

December

Source

Current Distribution

% of Current

 Distribution

Cumulative

Distributions

for the Fiscal

Year-to-Date

% of the Cumulative

Distributions for the Fiscal

Year-to-Date

Net Investment Income

$0.0066

8.60%

$0.0581

6.90%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Return of Capital or Other Capital Source(s)

$0.0694

91.40%

$0.7779

93.10%

Total per common share

$0.0760

100.00%

$0.8360

100.00%

Average annual total return at NAV for the 5-year period ended on October 31, 2019 1

4.53%

Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2019 2

10.00%

Cumulative total return at NAV for the fiscal year through October 31, 2019 3

10.65%

Cumulative fiscal year to date distribution rate as a percentage of NAV as of October 31, 2019 4

8.33%



Eaton Vance Tax-Advantaged Dividend Income Fund  (NYSE: EVT)

Distribution Period: 

November- 2019

Distribution Amount per Common Share: 

$0.1450

Distribution Frequency:

Monthly

Fiscal Year End:

October

Source

Current Distribution

% of Current

Distribution

Cumulative

Distributions

for the Fiscal

Year-to-Date

% of the Cumulative

Distributions for the Fiscal

Year-to-Date

Net Investment Income

$0.0260

18.00%

$0.0260

18.00%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.0190

13.00%

$0.0190

13.00%

Return of Capital or Other Capital Source(s)

$0.1000

69.00%

$0.1000

69.00%

Total per common share

$0.1450

100.00%

$0.1450

100.00%

Average annual total return at NAV for the 5-year period ended on October 31, 2019 1

9.88%

Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2019 2

7.15%

Cumulative total return at NAV for the fiscal year through October 31, 2019 3

16.02%

Cumulative fiscal year to date distribution rate as a percentage of NAV as of October 31, 2019 4

7.15%



Eaton Vance Tax-Advantaged Global Dividend Opportunities Fund  (NYSE: ETO)

Distribution Period: 

November- 2019

Distribution Amount per Common Share: 

$0.1800

Distribution Frequency:

Monthly

Fiscal Year End:

October

Source

Current Distribution

% of Current

Distribution

Cumulative

Distributions

for the Fiscal

Year-to-Date

% of the Cumulative

Distributions for the Fiscal

Year-to-Date

Net Investment Income

$0.0086

4.80%

$0.0086

4.80%

Net Realized Short-Term Capital Gains

$0.0616

34.20%

$0.0616

34.20%

Net Realized Long-Term Capital Gains

$0.1098

61.00%

$0.1098

61.00%

Return of Capital or Other Capital Source(s)

$0.0000

0.00%

$0.0000

0.00%

Total per common share

$0.1800

100.00%

$0.1800

100.00%

Average annual total return at NAV for the 5-year period ended on October 31, 2019 1

8.67%

Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2019 2

9.06%

Cumulative total return at NAV for the fiscal year through October 31, 2019 3

18.21%

Cumulative fiscal year to date distribution rate as a percentage of NAV as of October 31, 2019 4

9.06%



Eaton Vance Tax-Managed Buy-Write Income Fund (NYSE: ETB)

Distribution Period: 

November- 2019

Distribution Amount per Common Share: 

$0.1080

Distribution Frequency:

Monthly

Fiscal Year End:

December

Source

Current Distribution

% of Current

 Distribution

Cumulative

Distributions

for the Fiscal

Year-to-Date

% of the Cumulative

Distributions for the Fiscal

Year-to-Date

Net Investment Income

$0.0113

10.50%

$0.1307

11.00%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.0967

89.50%

$0.4075

34.30%

Return of Capital or Other Capital Source(s)

$0.0000

0.00%

$0.6498

54.70%

Total per common share

$0.1080

100.00%

$1.1880

100.00%

Average annual total return at NAV for the 5-year period ended on October 31, 2019 1

6.85%

Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2019 2

8.61%

Cumulative total return at NAV for the fiscal year through October 31, 2019 3

15.25%

Cumulative fiscal year to date distribution rate as a percentage of NAV as of October 31, 2019 4

7.18%



Eaton Vance Tax-Managed Buy-Write Opportunities Fund (NYSE: ETV)

Distribution Period: 

November- 2019

Distribution Amount per Common Share: 

$0.1108

Distribution Frequency:

Monthly

Fiscal Year End:

December

Source

Current Distribution

% of Current

 Distribution

Cumulative

Distributions

for the Fiscal

Year-to-Date

% of the Cumulative

Distributions for the Fiscal

Year-to-Date

Net Investment Income

$0.0064

5.80%

$0.0756

6.20%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Return of Capital or Other Capital Source(s)

$0.1044

94.20%

$1.1432

93.80%

Total per common share

$0.1108

100.00%

$1.2188

100.00%

Average annual total return at NAV for the 5-year period ended on October 31, 2019 1

8.71%

Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2019 2

9.27%

Cumulative total return at NAV for the fiscal year through October 31, 2019 3

16.08%

Cumulative fiscal year to date distribution rate as a percentage of NAV as of October 31, 2019 4

7.72%



Eaton Vance Tax-Managed Diversified Equity Income Fund (NYSE: ETY)

Distribution Period: 

November- 2019

Distribution Amount per Common Share: 

$0.0843

Distribution Frequency:

Monthly

Fiscal Year End:

October

Source

Current Distribution

% of Current

 Distribution

Cumulative

Distributions

for the Fiscal

Year-to-Date

% of the Cumulative

Distributions for the Fiscal

Year-to-Date

Net Investment Income

$0.0083

9.80%

$0.0083

9.80%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Return of Capital or Other Capital Source(s)

$0.0760

90.20%

$0.0760

90.2%

Total per common share

$0.0843

100.00%

$0.0843

100.0%

Average annual total return at NAV for the 5-year period ended on October 31, 2019 1

8.45%

Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2019 2

8.52%

Cumulative total return at NAV for the fiscal year through October 31, 2019 3

9.24%

Cumulative fiscal year to date distribution rate as a percentage of NAV as of October 31, 2019 4

8.52%



Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund (NYSE: ETW)

Distribution Period: 

November- 2019

Distribution Amount per Common Share: 

$0.0727

Distribution Frequency:

Monthly

Fiscal Year End:

December

Source

Current Distribution

% of Current

Distribution

Cumulative

Distributions

for the Fiscal

Year-to-Date

% of the Cumulative

Distributions for the Fiscal

Year-to-Date

Net Investment Income

$0.0121

16.60%

$0.1211

15.10%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.0606

83.40%

$0.1953

24.40%

Return of Capital or Other Capital Source(s)

$0.0000

0.00%

$0.4833

60.50%

Total per common share

$0.0727

100.00%

$0.7997

100.00%

Average annual total return at NAV for the 5-year period ended on October 31, 2019 1

6.18%

Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2019 2

8.48%

Cumulative total return at NAV for the fiscal year through October 31, 2019 3

14.39%

Cumulative fiscal year to date distribution rate as a percentage of NAV as of October 31, 2019 4

7.07%



Eaton Vance Tax-Advantaged Global Dividend Income (NYSE: ETG)

Distribution Period: 

November- 2019

Distribution Amount per Common Share: 

$0.1025

Distribution Frequency:

Monthly

Fiscal Year End:

October

Source

Current Distribution

% of Current

 Distribution

Cumulative

 Distributions

for the Fiscal

Year-to-Date

% of the Cumulative

Distributions for the Fiscal

Year-to-Date

Net Investment Income

$0.0265

25.80%

$0.0265

25.80%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Return of Capital or Other Capital Source(s)

$0.0760

74.20%

$0.0760

74.20%

Total per common share

$0.1025

100.00%

$0.1025

100.00%

Average annual total return at NAV for the 5-year period ended on October 31, 2019 1

7.19%

Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2019 2

7.03%

Cumulative total return at NAV for the fiscal year through October 31, 2019 3

13.06%

Cumulative fiscal year to date distribution rate as a percentage of NAV as of October 31, 2019 4

7.03%



Eaton Vance Tax-Managed Global Diversified Equity Income Fund (NYSE: EXG)

Distribution Period: 

November- 2019

Distribution Amount per Common Share: 

$0.0616

Distribution Frequency:

Monthly

Fiscal Year End:

October

Source

Current Distribution

% of Current

Distribution

Cumulative

Distributions

for the Fiscal

Year-to-Date

% of the Cumulative

Distributions for the Fiscal

Year-to-Date

Net Investment Income

$0.0041

6.60%

$0.0041

6.60%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Return of Capital or Other Capital Source(s)

$0.0575

93.40%

$0.0575

93.40%

Total per common share

$0.0616

100.00%

$0.0616

100.00%

Average annual total return at NAV for the 5-year period ended on October 31, 2019 1

6.46%

Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2019 2

8.50%

Cumulative total return at NAV for the fiscal year through October 31, 2019 3

12.85%

Cumulative fiscal year to date distribution rate as a percentage of NAV as of October 31, 2019 4

8.83%



Eaton Vance Tax-Managed Buy-Write Strategy Fund (NYSE: EXD)

Distribution Period: 

November- 2019

Distribution Amount per Common Share: 

$0.0708

Distribution Frequency:

Monthly

Fiscal Year End:

December

Source

Current Distribution

% of Current

Distribution

Cumulative

 Distributions

for the Fiscal

Year-to-Date

% of the Cumulative

Distributions for the Fiscal

Year-to-Date

Net Investment Income

$0.0044

6.20%

$0.0510

8.00%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Return of Capital or Other Capital Source(s)

$0.0664

93.80%

$0.5862

92.00%

Total per common share

$0.0708

100.00%

$0.6372

100.00%

Average annual total return at NAV for the 5-year period ended on October 31, 2019 1

2.02%

Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2019 2

8.24%

Cumulative total return at NAV for the fiscal year through October 31, 2019 3

9.51%

Cumulative fiscal year to date distribution rate as a percentage of NAV as of October 31, 2019 4

5.49%


1 Average annual total return at NAV represents the change in NAV of the Fund, with all distributions reinvested, for the 5-year period ended on October 31, 2019


2 The annualized current distribution rate is the cumulative distribution rate annualized as a percentage of the Fund’s NAV as of October 31, 2019


3 Cumulative total return at NAV is the percentage change in the Fund’s NAV for the period from the beginning of its fiscal year to October 31, 2019 including distributions paid and assuming reinvestment of those distributions.


4 Cumulative fiscal year distribution rate for the period from the beginning of its fiscal year to October 31, 2019 measured on the dollar value of the distributions in year-to-date period as a percentage of the Fund’s NAV as of October 31, 2019

 

Cision View original content:http://www.prnewswire.com/news-releases/eaton-vance-closed-end-funds-release-estimated-sources-of-distributions-300966846.html

SOURCE Eaton Vance Management